News from silence therapeutics plc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 05, 2012, 02:00 ET

US Allows Two Key Patents for Silence Therapeutics

Silence Therapeutics plc (AIM: SLN), a leading RNA interference (RNAi) therapeutics company, today announced that the US Patent and Trademark...

Oct 15, 2012, 02:00 ET

Appointment of Finance Director

Silence Therapeutics plc has appointed Tim Freeborn, 53, as its finance director. A chartered accountant, he joined the company from Xcap...

Sep 25, 2012, 02:00 ET

Silence Therapeutics plc Interim Results for the Six Months Ended 30 June 2012

Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today provides a corporate update and announces its...

Sep 18, 2012, 02:02 ET

Silence Therapeutics Appointment of Chief Medical Adviser

Silence Therapeutics plc (AIM: SLN), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Michael...

Sep 10, 2012, 02:00 ET

Significant Pre-Clinical Data in Acute Lung Injury

Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company is pleased to announce...

Aug 02, 2012, 04:00 ET

Silence Therapeutics - Admission of Shares and Board Update

Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company, announces that the New...

Jul 12, 2012, 02:00 ET

Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,...

Jun 06, 2012, 07:41 ET

Silence Therapeutics Announces Safe and Effective Dose Successfully Identified in Phase I Study of Atu027 and Potential Fund Raising

 Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, on...

May 17, 2012, 02:00 ET

New Data from Silence's Atu027 Anticancer Trial Published at ASCO

- Atu027, a First in Class RNAi Therapy, Demonstrates Potential - Antitumour Activity in Cancer Patients and Possible Biomarker...

May 03, 2012, 02:00 ET

Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication

Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, notes that its partner, Quark Pharmaceuticals, has...

Mar 21, 2012, 03:00 ET

Silence Therapeutics Forms Scientific Advisory Board and Forms Two New Research Collaborations to Further Strengthen Liver Pipeline

Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company, today announced the...

Mar 21, 2012, 03:00 ET

Silence Therapeutics Plc: Unaudited Preliminary Results for the Year Ended 31 December 2011

Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today announces its unaudited preliminary results for the...

Mar 09, 2012, 10:20 ET

Silence and Other Opponents of Tuschl I Patent Succeed in Limiting Scope and Ambiguity in the Patent

Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company, responds to comments...

Feb 10, 2012, 02:00 ET

Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer

-- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer -- -- Thomas Christély resigns as a Director of the Company...

Jan 09, 2012, 02:00 ET

Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics

- Third collaboration to investigate the potential application of Silence's proprietary RNAi delivery technologies in the development of novel...

Jan 06, 2012, 02:00 ET

Research and Development Collaboration Update

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces the successful...

Dec 20, 2011, 02:00 ET

Silence Therapeutics Additional Listing

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, today announces...

Dec 12, 2011, 02:00 ET

Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that...

Dec 07, 2011, 09:11 ET

Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces a positive...

Nov 08, 2011, 02:00 ET

Silence Therapeutics Provides Corporate and Development Update

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, today provides an update...